← Leaderboards
Scott Scarneo
Eydis Bio, Inc.
$3,698,654
Attributed
$6,391,215
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,391,215 · 6
By mechanism
R44$4,310,173 · 2
R43$1,074,950 · 2
R41$506,267 · 1
N43$499,825 · 1
Top collaborators
- Timothy A Haystead7 shared
Others in their field
Other Emerging Leaders on “Oral”
- Yunda Huang · Fred Hutchinson Cancer Center$53,780,853
- Susan Abushakra · Alzheon, Inc.$50,765,244
- John Damon Chodera · Sloan-Kettering Inst Can Research$40,061,627
- Jeffrey Reich · Sparian Biosciences, Inc.$28,575,028
- Gary Fanger · Rise Therapeutics, Llc$23,676,385
- James Dale Berry · Brigham And Women'S Hospital$15,344,018
Research focus
OralTransforming Growth Factor BetaInflammatoryInnovationIn VivoProtein KinaseCytokineScaffoldSignal TransductionElementsMediatingPathway InteractionsTreatment StrategyInflammationQuality Of CareCostResponseSignal PathwayDoseMouse ModelNuclearPre-ClinicalPharmaceutical ChemistryBiological Availability
Grant awards (9)
Novel compounds for the treatment of systemic sclerosis-associated interstitial lung disease$1,417,658
R44 · FY2025 · HL · contact PI
Discovery and Development of Oral Small-molecule Direct-acting Antivirals$499,825
N43 · FY2025 · AI · contact PI
Novel compounds for the treatment of systemic sclerosis-associated interstitial lung disease$1,182,632
R44 · FY2024 · HL · contact PI
Development of orally bioavailable and blood-brain barrier penetrant, small molecule TAK1 inhibitors as a novel treatment for Alzheimer's Disease$506,267
R41 · FY2024 · AG · contact PI
Preclinical Development of the TAK1 Inhibitor HS-276 for the Treatment of Rheumatoid Arthritis$913,097
R44 · FY2022 · AR · contact PI
Acute Inhibition of TAK1 as a Means to Control COVID-19 Pulmonary Hyperinflammation$284,707
R43 · FY2022 · HL · contact PI
Preclinical Development of the TAK1 Inhibitor HS-276 for the Treatment of Rheumatoid Arthritis$796,786
R44 · FY2021 · AR · contact PI
Evaluating the Blood-Brain Barrier Bioavailability and in vivo Efficacy Potential of a Novel TAK1 Inhibitor Targeting Chronic Pain$480,955
R43 · FY2021 · NS · contact PI
Acute Inhibition of TAK1 as a Means to Control COVID-19 Pulmonary Hyperinflammation$309,288
R43 · FY2021 · HL · contact PI